Regeneron Pharmaceuticals... (REGN)
665.68
-12.74 (-1.88%)
At close: Mar 18, 2025, 3:59 PM
668.73
0.46%
After-hours: Mar 18, 2025, 07:55 PM EDT
-1.88% (1D)
| Bid | 662.46 |
| Market Cap | 71.57B |
| Revenue (ttm) | 14.19B |
| Net Income (ttm) | 4.41B |
| EPS (ttm) | 38.33 |
| PE Ratio (ttm) | 17.37 |
| Forward PE | 15.46 |
| Analyst | Buy |
| Ask | 675 |
| Volume | 447,124 |
| Avg. Volume (20D) | 976,420.1 |
| Open | 678.00 |
| Previous Close | 678.42 |
| Day's Range | 664.95 - 678.13 |
| 52-Week Range | 642.00 - 1211.20 |
| Beta | 0.27 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlus...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 2, 1991
Employees 15,106
Stock Exchange NASDAQ
Ticker Symbol REGN
Website https://www.regeneron.com
Analyst Forecast
According to 22 analyst ratings, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $1065, which is an increase of 59.99% from the latest price.
Stock ForecastsNext Earnings Release
Regeneron Pharmaceuticals Inc. is scheduled to release its earnings on May 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 days ago
-2.02%
Regeneron Pharmaceuticals shares are trading lower...
Unlock content with
Pro Subscription
1 month ago
+4.53%
Regeneron shares are trading higher after the company reported better-than-expected Q4 financial results. The company also approved a $3 billion share repurchase program and initiated a quarterly cash dividend.
